Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program
Open Access
- 2 November 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 36 (11) , 669-675
Abstract
Resting heart rate (HR) is a predictor of adverse outcome in patients with heart failure (HF). Whether changes in HR over time in patients with chronic HF are also associated with adverse outcome is unknown. We explored the relationship between changes in HR from a preceding visit, time-updated HR (i.e. most recent available HR value from a clinic visit) and subsequent outcomes in patients with chronic HF. We studied 7599 patients enrolled in the candesartan in heart failure: assessment of reduction in mortality and morbidity program. We calculated change in HR from the preceding visit and explored its association with outcomes in Cox proportional hazards models, as well the association between time-updated HR and outcome. An increase in HR from preceding visit was associated with a higher risk of all-cause mortality and the composite endpoint of cardiovascular death or hospitalization for HF (adjusted hazard ratio 1.06, 95% confidence intervals, CI: 1.05–1.08, P < 0.001, per 5 b.p.m. higher HR), with lowering of HR being associated with lower risk, adjusting for covariates, including time-updated β-blocker dose and baseline HR. Time-updated resting HR at each visit was also associated with risk (adjusted hazard ratio 1.07, 95% CI: 1.06–1.09; P < 0.001, per 5 b.p.m. higher HR). Change in HR over time predicts outcome in patients with chronic HF, as does time-updated HR during follow-up. These data suggest that frequent outpatient monitoring of HR, and identification of changes over time, possibly with remote technologies, may identify patients with HF who may be at increased risk of rehospitalization or death.Keywords
This publication has 20 references indexed in Scilit:
- Association of Heart Rate and Outcomes in a Broad Spectrum of Patients With Chronic Heart FailureJACC, 2012
- Effects on Outcomes of Heart Rate Reduction by Ivabradine in Patients With Congestive Heart Failure: Is There an Influence of Beta-Blocker Dose?JACC, 2012
- Temporal Changes in Resting Heart Rate and Deaths From Ischemic Heart DiseaseJAMA, 2011
- Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trialThe Lancet, 2010
- Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled studyThe Lancet, 2010
- Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart FailureAnnals of Internal Medicine, 2009
- Relation of Heart Rate at Rest and Long-Term (>20 Years) Death Rate in Initially Healthy Middle-Aged MenThe American Journal of Cardiology, 2009
- Resting Heart Rate in Cardiovascular DiseaseJACC, 2007
- Elevated Heart Rate: A Major Risk Factor for Cardiovascular DiseaseClinical and Experimental Hypertension, 2004
- Mode of death in heart failure: findings from the ATLAS trialHeart, 2003